New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD)

References

• Ferrara JLM, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561.
   PubMed Web of Science ®Google Scholar
• Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol. 2011;2011:1–8.
   Google Scholar
• Arai S, Margolis J, Zahurak M, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2002;8(3):155–160.
   PubMed Web of Science ®Google Scholar
• Giesler S, Zeiser R. Deciphering the role of Minor histocompatibility antigens for acute graft-versus-host disease. Transplant Cell Ther. 2021;27(7):523–524
   PubMedGoogle Scholar
• Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood. 2002;100(6):1977–1983.
   PubMed Web of Science ®Google Scholar
• Gooptu M, Antin JH. GVHD Prophylaxis 2020. Front Immunol. 2021;12:605726.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Robin M, Harris AC, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21(4):761–767.
   PubMed Web of Science ®Google Scholar
• Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21–e29.
   PubMed Web of Science ®Google Scholar
• Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855–864.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Ferrara JLM, Chaudhry MS. GVHD: biology matters. Blood Adv. 2018;2(22):3411–3417.
   PubMed Web of Science ®Google Scholar
• Srinagesh HK, Özbek U, Kapoor U, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034–4042.
   PubMed Web of Science ®Google Scholar
• McDonald GB, Tabellini L, Storer BE, et al. Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood. 2015;126(1):113–120.
   PubMed Web of Science ®Google Scholar
• Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2008;113:273–278.
   PubMed Web of Science ®Google Scholar
• Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529–539.
   PubMed Web of Science ®Google Scholar
• Ferrara JLM, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118(25):6702–6708.
   PubMed Web of Science ®Google Scholar
• Hartwell MJ, Özbek U, Holler E, et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017;2(3):e89798.
   PubMed Web of Science ®Google Scholar
• Major-Monfried H, Renteria AS, Pawarode A, et al. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018;131(25):2846–2855.
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a blood and marrow transplant clinical trials network study. Blood. 2012;119(16):3854–3860.
   PubMed Web of Science ®Google Scholar
• Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood. 2012;120(1):223–231.
   PubMed Web of Science ®Google Scholar
• Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020;382(9):822–834.
   PubMed Web of Science ®Google Scholar
• Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017;23(5):845–852.
   PubMed Web of Science ®Google Scholar
• Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016;17(5):505–513.
   PubMed Web of Science ®Google Scholar
• Reddy P, Ferrara JLM. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–194.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305.
   PubMed Web of Science ®Google Scholar
• Sun Y, Tawara I, Toubai T, et al. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res J Lab Clin Med. 2007;150:197–214.
   Google Scholar
• Al-Homsi AS, Roy TS, Cole K, et al. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21(4):604–611.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638–647.
   PubMed Web of Science ®Google Scholar
• O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2002;8(7):377–386.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Alousi AM, Bolaños-Meade J, Lee SJ. Graft-versus-host disease: state of the science. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2013;19(1):S102–108.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.
   PubMed Web of Science ®Google Scholar
• Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32(5):605–615.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SAE, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202.
   PubMed Web of Science ®Google Scholar
• Fu -Y-Y, Egorova A, Sobieski C, et al. T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation. Immunity. 2019;51(1):90–103.e3.
   PubMed Web of Science ®Google Scholar
• Takashima S, Martin ML, Jansen SA, et al. T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage. Sci Immunol. 2019;4(42):eaay8556.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Luo L, Subramaniam S, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25(2):e328–e334.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18(8):1150–1163.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800–1810.
   PubMed Web of Science ®Google Scholar
• Zeiser R. GRAVITAS-301: a randomized, double-blind phase 3 study of itacitinib or placebo in combination with corticosteroids for initial treatment of patients with acute graft-versus-host disease. 2020.
   Google Scholar
• Watkins BK, Qayed M, Bratrude B, et al. T cell costimulation blockade with CTLA4-Ig (Abatacept) for acute gvhd prevention in HLA matched and mismatched unrelated donor transplantation: results of the first phase 2 trial. Biol Blood Marrow Transplant. 2019;25(3):S51–S52.
   Web of Science ®Google Scholar
• Van Oosterhout YV, Van Emst L, Schattenberg AV, et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood. 2000;95(12):3693–3701.
   PubMed Web of Science ®Google Scholar
• Groth C, Van Groningen LFJ, Matos TR, et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25(4):712–719.
   PubMed Web of Science ®Google Scholar
• Murai M, Yoneyama H, Ezaki T, et al. Peyer’s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol. 2003;4(2):154–160.
   PubMed Web of Science ®Google Scholar
• Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204–3213.
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Docampo MD, Riwes M, et al. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nat Commun. 2018;9(1):3674.
   PubMedGoogle Scholar
• Hanash AM, Dudakov JA, Hua G, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012;37(2):339–350.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ramadan AM, Griesenauer B, et al. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med. 2015;7(308):308ra160.
   PubMed Web of Science ®Google Scholar
• Zhao D, Kim Y-H, Jeong S, et al. Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest. 2018;128(11):4970–4979.
   PubMed Web of Science ®Google Scholar
• Yamada R, Nemoto T, Ohashi K, et al. Distribution of transplantation-associated thrombotic microangiopathy (TA-TMA) and Comparison between renal TA-TMA and Intestinal TA-TMA: autopsy Study. Biol Blood Marrow Transplant. 2020;26(1):178–188.
   PubMed Web of Science ®Google Scholar
• Wall SA, Zhao Q, Yearsley M, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018;2(20):2619–2628.
   PubMed Web of Science ®Google Scholar
• Ruutu T, Juvonen E, Remberger M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20(1):135–138.
   PubMedGoogle Scholar
• Berlin C, Berg EL, Briskin MJ, et al. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74(1):185–195.
   PubMed Web of Science ®Google Scholar
• Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol Baltim Md 1950. 1994;153:517–528.
   Google Scholar
• Danylesko I, Bukauskas A, Paulson M, et al. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplant. 2019;54(7):987–993.
   PubMed Web of Science ®Google Scholar
• Chen Y-B, McDonough S, Chen H, et al. Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013;48(4):598–603.
   PubMed Web of Science ®Google Scholar
• Fløisand Y, Lazarevic VL, Maertens J, et al. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25(4):720–727.
   PubMed Web of Science ®Google Scholar
• Kekre N, Kim HT, Ho VT, et al. Phase II trial of natalizumab (Tysabri®) with corticosteroids as initial treatment of gastrointestinal acute graft versus host disease. Biol Blood Marrow Transplant. 2018;24(3):S81.
   Web of Science ®Google Scholar
• Van Der Waart AB, Van Der Velden WJFM, Blijlevens NM, et al. Targeting the IL17 pathway for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20(6):752–759.
   PubMed Web of Science ®Google Scholar
• Coghill JM, Sarantopoulos S, Moran TP, et al. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood. 2011;117(12):3268–3276.
   PubMed Web of Science ®Google Scholar
• Ganetsky A, Frey NV, Hexner EO, et al. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant. 2019;54(2):212–217.
   PubMed Web of Science ®Google Scholar
• Roddy JVF, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2016;57(1):81–85.
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451–1459.
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Witte E, et al. IL-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–254.
   PubMed Web of Science ®Google Scholar
• Geboes L, Dumoutier L, Kelchtermans H, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009;60(2):390–395.
   PubMed Web of Science ®Google Scholar
• Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by Acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29(2):210–214.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest. 2008;118:534–544.
   PubMed Web of Science ®Google Scholar
• Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity. 2008;29(6):947–957.
   PubMed Web of Science ®Google Scholar
• Pickert G, Neufert C, Leppkes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. 2009;206(7):1465–1472.
   PubMed Web of Science ®Google Scholar
• Ponce DM, Alousi AM, Nakamura R, et al. A phase 2 study of F-652, a novel tissue-targeted recombinant human interleukin-22 (IL-22) dimer, for treatment of newly diagnosed acute GVHD of the lower GI tract. Biol Blood Marrow Transplant. 2020;26(3):S51–S52.
   Web of Science ®Google Scholar
• Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214.
   PubMed Web of Science ®Google Scholar
• Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;55(7):905–914.
   PubMed Web of Science ®Google Scholar
• Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209(5):903–911.
   PubMed Web of Science ®Google Scholar
• Taur Y, Jenq RR, Perales M-A, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174–1182.
   PubMed Web of Science ®Google Scholar
• Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2014;20(5):640–645.
   PubMed Web of Science ®Google Scholar
• Peled JU, Hanash AM, Jenq RR. Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood. 2016;128(20):2395–2402.
   PubMed Web of Science ®Google Scholar
• Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083–2088.
   PubMed Web of Science ®Google Scholar
• Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018;10(460).
   PubMed Web of Science ®Google Scholar
• Pott GB, Chan ED, Dinarello CA, et al. α-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85(5):886–895.
   PubMed Web of Science ®Google Scholar
• Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564–569.
   PubMed Web of Science ®Google Scholar
• Magenau JM, Goldstein SC, Peltier D, et al. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018;131(12):1372–1379.
   PubMed Web of Science ®Google Scholar
• Gergoudis SC, DeFilipp Z, Özbek U, et al. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin. Blood Adv. 2020;4(24):6098–6105.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang C, Yin J, et al. Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PloS One. 2015;10(8):e0136991.
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30(1):42–48.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Fazekasova H, Lam EW-F, et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 2007;83(1):71–76.
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367–372.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Cutler A, Doree C, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019;1:CD009768.
   PubMedGoogle Scholar
• Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10(1):182.
   PubMedGoogle Scholar
• Kurtzberg J, Abdel-Azim H, Carpenter P, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2020;26(5):845–854.
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144–1150.
   PubMed Web of Science ®Google Scholar
• Riegel C, Boeld TJ, Doser K, et al. Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Leukemia. 2020;34(3):895–908.
   PubMed Web of Science ®Google Scholar
• Cao T, Soto A, Zhou W, et al. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol. 2009;258(1):65–71.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, McKenna DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016;127:1044–1051.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–3928.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–1070.
   PubMed Web of Science ®Google Scholar
• Betts BC, Pidala J, Kim J, et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017;102:948–957.
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Dennis M, Jilani NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–3369.
   PubMed Web of Science ®Google Scholar
• Saad A, De Lima M, Anand S, et al. Hematopoietic cell transplantation, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2020;18(5):599–634.
   PubMed Web of Science ®Google Scholar